Responses to an interview study demonstrated that patient education on palliative care led to better understanding of its benefits and greater utilization of these services.

Adjuvant cemiplimab could be a new standard of care for patients with cutaneous squamous cell carcinoma at high risk of recurrence, according to Danny Rischin, MD.